OBJECTIVE: To assess whether supplementation with @entity7447 ( @entity7447 ) during pregnancy reduces the risk of @entity1468 . METHODS: @entity1 at increased risk of @entity1468 were enrolled in a randomized, double-blind, placebo-controlled trial. @entity1 were assigned to receive 200 mg of @entity7447 or placebo daily from 20 weeks of pregnancy until delivery. The primary outcome was rate of @entity1468 . Statistical analyses were by intention-to-treat. RESULTS: Of the 235 @entity1 enrolled in the trial, 118 were randomized to receive @entity7447 and 117 received a placebo. A total of 197 (83.8%) @entity1 were followed-up. The overall rate of @entity1468 was 20% (n=47). Thirty @entity1 (25.6%) in the placebo group developed @entity1468 compared with 17 @entity1 (14.4%) in the @entity7447 group, and this reduction was significant (P=0.035) (relative risk [RR] 0.56; 95% confidence interval [CI], 0.33-0.96). CONCLUSION: Supplementation with @entity7447 reduces the risk of developing @entity1468 in @entity1 at risk for the condition.

XXXX supplementation during pregnancy reduces the risk of @entity1468 .

@entity1 :: ('9606', 'Species') :: ['women', 'Women'] @entity1468 :: ('MESH:D011225', 'Disease') :: ['pre-eclampsia'] @entity7447 :: ('MESH:C024989', 'Chemical') :: ['Coenzyme Q10', 'CoQ10']
@entity7447 :: (MESH:C024989,Chemical) :: ['Coenzyme Q10']
